BioSpace News Archive

Gain Therapeutics, Inc. today announced additional details on its R&D Day being held virtually on Friday, February 4, 2022 from 10:00 am – 12:00 pm Eastern Time.

Augmedix, Inc. today announced preliminary unaudited financial and operational results for the three months ended December 31, 2021.

Valneva SE today announced the initiation of a Phase 3 trial in adolescents for its single-shot chikungunya vaccine candidate, VLA1553.

Gamida Cell Ltd. today announced the addition of Anat Cohen-Dayag, Ph.D., and Naama Halevi-Davidov, Ph.D., to its Board of Directors as Class II Directors.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 35 individuals hired by Sarepta in January 2022.

ImmunityBio, Inc., a clinical-stage immunotherapy company, announced promising study results that demonstrate the activation of CD4+ and CD8+ T cells and natural killer cells in people living with HIV by ImmunityBio’s IL-15 superagonist Anktiva.

Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data for the company’s Decipher urologic cancer tests will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif., and virtually, February 17-19, 2022.

Beroni Group, an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has signed a contract to build a new Research & Development centre in the Zhuhai National High-Tech Industrial Development Zone in China.

Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp., a publicly traded special purpose acquisition company, announced they have entered into a business combination agreement.

TheBarbara Ann Karmanos Cancer Institute recently received a $352,437 grant from the U CAN-CER VIVE Foundation to help fund a pancreatic cancer research study.